{"name":"Intellia Therapeutics, Inc.","slug":"intellia","ticker":"NTLA","exchange":"NASDAQ","domain":"intelliatx.com","description":"Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell the","hq":"Cambridge, MA","founded":2014,"employees":"377","ceo":"John Leonard","sector":"Gene Editing / Biotech","stockPrice":13.46,"stockChange":-0.82,"stockChangePercent":-5.74,"marketCap":"$1.9B","metrics":{"revenue":66092000,"revenueGrowth":-9.5,"grossMargin":0,"rdSpend":0,"netIncome":-394596000,"cash":375985984,"dividendYield":0,"peRatio":-7.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Intellia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Intellia reported fourth quarter and full year 2023 financial results, including revenue of $13.6 million and a net loss of $143.6 million.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Intellia Therapeutics and Regeneron Pharmaceuticals Announce Collaboration to Develop CRISPR/Cas9 Gene Editing Therapies","summary":"Intellia and Regeneron announced a collaboration to develop CRISPR/Cas9 gene editing therapies for various diseases.","drugName":"","sentiment":"positive"},{"date":"2023-09-18","type":"trial","headline":"Intellia Therapeutics Announces Positive Interim Results from Phase 1/2a Clinical Trial of NTLA-2001","summary":"Intellia announced positive interim results from a Phase 1/2a clinical trial of NTLA-2001, a CRISPR/Cas9 gene editing therapy for sickle cell disease.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxObW5BWHc4SzNGck5seXQ0ZDN0QU5fUmZVSkhyUnVmRUpQcmNFX3pMYkwzcnpHZVVBcVVJckxiV0dubEM0eDVvR0JudHJpX3JzN09tUFZ6SGUwT3BuaVB5LVlGMkhVNVRjelk5clpZV3EwYTVMTHRkY2JLX3FnZkZVMlZUVjVHaHp4S1ZFanpxbTFaTEgxb0xOci1vSFZMVWhkWW5neTlXVXNpRXdIQktCeDFGUDE5VkpPcDhTREt3WU1UcHRCWnBSTFNTQW9TS3FsRVZZV0trZks?oc=5","date":"2026-03-02","type":"regulatory","source":"Reuters","summary":"Intellia gets FDA nod to resume second gene therapy trial after safety pause - Reuters","headline":"Intellia gets FDA nod to resume second gene therapy trial after safety pause","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNVGxjLWZhekx3dkY4bGdmLWdYRFJRUm1rdXZnejRWVnZpbHcybDdRQnB6UjFOZDR0VHhlVTRkWk1YVkhXRXJrNUpDNXk2cFY4RnA0S2F1ZHNEOWZkMDFNTkVaSnJJbzkxNVNTa3EyRHNWR2xPaFBIWHgyR3dWY2lESWlSNmxkNDhTaExFdlFDSVlWWVBsYkFDTw?oc=5","date":"2026-02-27","type":"earnings","source":"Finviz","summary":"Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline - Finviz","headline":"Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQ1hpbEZhUEM4UXFzdGVtZG5vRG0xNlR6MG1xRldKemZSdEI1d2pYMXlJRElaUTh1VXZPRy1Bb1B2MEtLNU9IRUxvV1JOSklEdkpwZzBHeVV5ZTlfajU1aU9ZMjNNNmViMzJvRUp6clFBWUZpYzRNY1RGelJaWTNfcFQ4SE8xVGcxT2FvdlRSRENkaURObDF6M3loZWZqMmozTzZiOXowbDFtTEJ1WEtPVEM0cWNYWDlMaEZNc0lnYw?oc=5","date":"2026-02-23","type":"earnings","source":"TradingView","summary":"What's in Store for These 5 Medical Companies This Earnings Season? - TradingView","headline":"What's in Store for These 5 Medical Companies This Earnings Season?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1LVzQxbTd5SlM0VzVDWWU4dGxVUUk1SGFkc3RncGc4OFB5dTJfN1VQS3pzVGVWV3RtZjJ5NHBRc3FqLVBBTmMzS2pKRkxiQXhEeEhPWGs2ejVmTlRQUkZiRDhaTmg1TVNpRmc?oc=5","date":"2026-02-05","type":"deal","source":"Morningstar","summary":"The Best Biotech Stocks to Buy - Morningstar","headline":"The Best Biotech Stocks to Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNMVY5VzhwV0Z0aFhDRy1DVE5mY1lvU2xOZGtvRExDWXptUGdqb1hiT3RaSkZpX0VzNFM0NUExakJ2eDhITWkwNHFkOHpmVVlYWndsUExzMjV1Z2J1Nzg1VjkzX2tvUjk4RTlfZzE0X3dHbkN2ck9YdEZvaWZmOTc5M01jOWFNMjhhUzJ5eHlPa3ZsVnRVaUlSV0k0RWkyNGdudmljR0RFMG5PV01YZWlydUlCcVFtQ2Z2ZXBKQXlqMG1qLW8?oc=5","date":"2026-01-27","type":"regulatory","source":"Intellia Therapeutics - investor relations","summary":"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia Therapeutics - investor relations","headline":"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN - Intellia T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNTkpqcy04aGFlSDJ0dFBtZlRIdUVFVWVhUGp6VW1aY1ZNTkZGdVBTYTRWQUJNQ2dpN0tZTnRqMElPdkxBMEdzVDllZ2ttdkQxX0hoMnVZMHFEOFZvUU43ZnEzUVBXVEpQRmFXcFhvcEY5OXIyVDlwMEFodGpBeUFCWHhUUmphMnM3enZXcTduaU10UjRVNVhxYTdxaEZWQ0Y0bWp3dkpOdmtOdTNRakRvbjNn?oc=5","date":"2026-01-05","type":"pipeline","source":"TradingView","summary":"Intellia Stock Declines Around 55% in 3 Months: Here's Why - TradingView","headline":"Intellia Stock Declines Around 55% in 3 Months: Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOQWdzZjhRekNab1NEbGdpc3k4SVFlaVlndlVvQ3pNUGVGRlZ6emk4THB2dEdSMndBRjlJcmZRVFN4M1Jua3IxYmJpc2hvUTFnakVMOHlKU2YzU1l5SDdrX0I0UVFvYlNvMG9MOGZYaGlQME5hZ3dDb3pFdnJKWXBqZDl2SmdHczVpaHJ6ZHNWWVJwR1RtVHIyMW8xNDFhT2dpQ1daZHI2LXltZi1tV2hiMTlyb05PbUZz?oc=5","date":"2025-12-02","type":"pipeline","source":"Seeking Alpha","summary":"Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility (NTLA) - Seeking Alpha","headline":"Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility (NTLA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQZHc5dUUtQmpoakRmVUV5OUFrS2tXWXJpcDdndmpvZl9RcFdUc29feGNUN2lIT1I2QUJVRFdNbXE3aEpMcVhhRHdaaWtZdkktaFFfTEpfUGQ0ZWdmWC1pdmVyWWZWcFpxTmprU2xYTUEzOUlnLWYyQmNRYmI4RUFieXhWMEk1dFVNWlMzVlNET2pBczJMMnJfYjFhdHc?oc=5","date":"2025-11-21","type":"deal","source":"Finviz","summary":"NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock? - Finviz","headline":"NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQb3lIeTgyNXJ2ZFVJRTFpeE1jTjM1SHRIcDNQQUZtSUtRWFJXaUd2WGNWTHZpSkd1SXVtUXJydkVQRkt2UlhnM1JFUU15dWVrdzUzeVBRR1FRN3BXdlh4QnRGanBiTE9mcVZheTBJaFNiR3FENFVwVGZ4X2pwUHJrRl9qcU01cW1TNFlOVzRSbzJmQmxiOHBEX05vOF9CR1ZrQUlfQ3VDekxVbjRZd1JN?oc=5","date":"2025-10-31","type":"regulatory","source":"MedCity News","summary":"Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease - MedCity News","headline":"Liver Complications Lead FDA to Stop Tests of Intellia Gene-Editing Therapy for a Rare Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTFBVbU9KUjZIWE5yVkFzSS10NjlFM2pQRTRfNnp1T1RnTHRVVHlHY0QxbExvVFp1TE1IV2tXSWJrWTBZY3JTdEN1ZXVFckxMM0ZrMk5jdEZhT2hfQVpIeG9QRXRKWEU1b1pHbk1zZmdVajVqWnFIam92OTJBRW5xbDJ1QTRIVl9PazFReUtHSzRGM25HSTZwT05jbnhNWDNfLVlrTlRLd2QwSjM0MEVQWWhaTF9FemIzS2ZxREg5NGhRZw?oc=5","date":"2025-10-27","type":"trial","source":"Intellia Therapeutics - investor relations","summary":"Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeutics - investor relations","headline":"Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - Intellia Therapeuti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNVFQ2TFdheFhnTUtuY2VsS0hfSE9LcFFrZVNVMFR6eVZQVUg2eTVmNG8xM1BRMUg2YVhNQURSb1NVVURRbU1TY2s4TTR4bWdMRFFUNE4zbGVROTZEalVOWURMOHhZYTVhOG52SDQ0azJ5dzVqaTl0eUFRYTg3VTBxRkgtY29oVFNOUm9feHlFaUtRaWlRTFUyZ2tzdGFtQmVJSzR4WTlTb25QSXV6ZnZvbXFaVlc4c2hvUmc5OE5R?oc=5","date":"2025-10-27","type":"trial","source":"Stock Titan","summary":"Intellia Therapeutics (NASDAQ: NTLA) pauses Phase 3 MAGNITUDE trials; more than 650 enrolled - Stock Titan","headline":"Intellia Therapeutics (NASDAQ: NTLA) pauses Phase 3 MAGNITUDE trials; more than 650 enrolled","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOZEJlMzJjZ19ybDFwVERNaEZ5bHgyOHZlUDNvQ0tCLWRPdFpEazlaSkpiMTFtNlhqbWhKV19VTWR0ZVhvTGthem0xX0J2eG5vRUlyNjBtV1pxNThCUmNCakRJQ2lpbE5FLUR1czZiTFBveGpOVHBQdHBmWUg3V3llSVdHUGpEekZIMjFZQVEyemZ4MjljX1hFWXJ2Q2JjVWxRRldVc3dENXN6NjM5SzQ1UXRlU3NFelpMR2c?oc=5","date":"2025-09-19","type":"trial","source":"Seeking Alpha","summary":"Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis (NTLA) - Seeking Alpha","headline":"Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis (NTLA)","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Beam Therapeutics"],"therapeuticFocus":["Gene Editing","Sickle Cell Disease","Transthyretin Amyloidosis"],"financials":{"source":"yahoo_finance","revenue":67671000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":67671000},{"period":"2024-12-31","value":57877000},{"period":"2023-12-31","value":36275000},{"period":"2022-12-31","value":52121000}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":388861000,"rdSpendHistory":[{"period":"2025-12-31","value":388861000},{"period":"2024-12-31","value":466311000},{"period":"2023-12-31","value":435069000},{"period":"2022-12-31","value":419979000}],"sgaSpend":119800000,"operatingIncome":-440990000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-440990000},{"period":"2024-12-31","value":-534263000},{"period":"2023-12-31","value":-515291000},{"period":"2022-12-31","value":-458164000}],"netIncome":-412694000,"netIncomeHistory":[{"period":"2025-12-31","value":-412694000},{"period":"2024-12-31","value":-519021000},{"period":"2023-12-31","value":-481192000},{"period":"2022-12-31","value":-474186000}],"eps":-3.81,"epsHistory":[{"period":"2025-12-31","value":-3.81},{"period":"2024-12-31","value":-5.25},{"period":"2023-12-31","value":-5.42},{"period":"2022-12-31","value":-6.16}],"cash":155464000,"cashHistory":[{"period":"2025-12-31","value":155464000},{"period":"2024-12-31","value":189182000},{"period":"2023-12-31","value":226748000},{"period":"2022-12-31","value":523506000}],"totalAssets":842127000,"totalLiabilities":170733000,"totalDebt":93329000,"equity":671394000,"operatingCashflow":-394736000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-394736000},{"period":"2024-12-31","value":-348880000},{"period":"2023-12-31","value":-394086000},{"period":"2022-12-31","value":-333287000}],"capex":-1129000,"capexHistory":[{"period":"2025-12-31","value":-1129000},{"period":"2024-12-31","value":-5778000},{"period":"2023-12-31","value":-13985000},{"period":"2022-12-31","value":-58390000}],"freeCashflow":-395865000,"dividendsPaid":null,"buybacks":null,"employees":377,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":33075000,"ebit":-98710000,"ebitda":-92695000,"period":"2025-12-31","revenue":23017000,"epsBasic":-0.83,"netIncome":-95786000,"rdExpense":88652000,"epsDiluted":-0.83,"grossProfit":null,"operatingIncome":-98710000},{"sga":30512000,"ebit":-111477000,"ebitda":-106541000,"period":"2025-09-30","revenue":13782000,"epsBasic":-0.92,"netIncome":-101324000,"rdExpense":94747000,"epsDiluted":-0.92,"grossProfit":null,"operatingIncome":-111477000},{"sga":27206000,"ebit":-109996000,"ebitda":-107522000,"period":"2025-06-30","revenue":14245000,"epsBasic":-0.98,"netIncome":-101255000,"rdExpense":97035000,"epsDiluted":-0.98,"grossProfit":null,"operatingIncome":-109996000},{"sga":29007000,"ebit":-120807000,"ebitda":-118309000,"period":"2025-03-31","revenue":16627000,"epsBasic":-1.1,"netIncome":-114329000,"rdExpense":108427000,"epsDiluted":-1.1,"grossProfit":null,"operatingIncome":-120807000},{"sga":32444000,"ebit":-136447000,"ebitda":-133881000,"period":"2024-12-31","revenue":12874000,"epsBasic":-1.27,"netIncome":-128898000,"rdExpense":116877000,"epsDiluted":-1.27,"grossProfit":null,"operatingIncome":-136447000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":13.46,"previousClose":14.28,"fiftyTwoWeekHigh":28.25,"fiftyTwoWeekLow":6.83,"fiftyTwoWeekRange":"6.83 - 28.25","fiftyDayAverage":13.66,"twoHundredDayAverage":13.2,"beta":1.93,"enterpriseValue":1699738112,"forwardPE":-7.1,"priceToBook":2.61,"priceToSales":28.44,"enterpriseToRevenue":25.72,"enterpriseToEbitda":-4.13,"pegRatio":0,"ebitda":-411244000,"ebitdaMargin":0,"freeCashflow":-235232880,"operatingCashflow":-363152000,"totalDebt":80490000,"debtToEquity":13,"currentRatio":6.1,"returnOnAssets":-30.1,"returnOnEquity":-56.3,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":20,"targetMeanPrice":26.55,"targetHighPrice":95,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":3.8,"institutionHeldPercent":76,"sharesOutstanding":139722277,"floatShares":134158536,"sharesShort":43531487,"shortRatio":6.78,"shortPercentOfFloat":31.2,"epsTrailing":-3.52,"epsForward":-1.89,"revenuePerShare":0.59,"bookValue":5.16,"officers":[{"age":68,"name":"Dr. John M. Leonard M.D.","title":"President, CEO & Director"},{"age":49,"name":"Mr. Edward J. Dulac III","title":"Executive VP, CFO & Treasurer"},{"age":62,"name":"Dr. Birgit  Schultes Ph.D.","title":"Executive VP & Chief Scientific Officer"},{"age":59,"name":"Mr. James E. Basta Esq., J.D.","title":"Executive VP, General Counsel & Corporate Secretary"},{"age":70,"name":"Dr. David  Lebwohl M.D.","title":"Executive VP & Chief Medical Officer"},{"age":39,"name":"Dr. Rachel E. Haurwitz Ph.D.","title":"Co-Founder"},{"age":61,"name":"Dr. Jennifer A. Doudna Ph.D.","title":"Founder & Member of Scientific Advisor Board"},{"age":null,"name":"Dr. Derrick J. Rossi Ph.D.","title":"Founder & Member of Scientific Advisor Board"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.intelliatx.com","phone":"857 285 6200"}}